237 related articles for article (PubMed ID: 33387629)
1. Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine.
Plaze M; Attali D; Prot M; Petit AC; Blatzer M; Vinckier F; Levillayer L; Chiaravalli J; Perin-Dureau F; Cachia A; Friedlander G; Chrétien F; Simon-Loriere E; Gaillard R
Int J Antimicrob Agents; 2021 Mar; 57(3):106274. PubMed ID: 33387629
[TBL] [Abstract][Full Text] [Related]
2. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
[TBL] [Abstract][Full Text] [Related]
3. Repurposing chlorpromazine to treat COVID-19: The reCoVery study.
Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
Encephale; 2020 Jun; 46(3):169-172. PubMed ID: 32425222
[TBL] [Abstract][Full Text] [Related]
4. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2
Weston S; Coleman CM; Haupt R; Logue J; Matthews K; Li Y; Reyes HM; Weiss SR; Frieman MB
J Virol; 2020 Oct; 94(21):. PubMed ID: 32817221
[TBL] [Abstract][Full Text] [Related]
5. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
Hahn F; Wangen C; Häge S; Peter AS; Dobler G; Hurst B; Julander J; Fuchs J; Ruzsics Z; Überla K; Jäck HM; Ptak R; Muehler A; Gröppel M; Vitt D; Peelen E; Kohlhof H; Marschall M
Viruses; 2020 Dec; 12(12):. PubMed ID: 33291455
[TBL] [Abstract][Full Text] [Related]
6. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses
Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT
mBio; 2021 Jan; 12(1):. PubMed ID: 33468703
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of itraconazole against SARS-CoV-2.
Van Damme E; De Meyer S; Bojkova D; Ciesek S; Cinatl J; De Jonghe S; Jochmans D; Leyssen P; Buyck C; Neyts J; Van Loock M
J Med Virol; 2021 Jul; 93(7):4454-4460. PubMed ID: 33666253
[TBL] [Abstract][Full Text] [Related]
8. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
9. Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus.
Terrier O; Dilly S; Pizzorno A; Chalupska D; Humpolickova J; Bouřa E; Berenbaum F; Quideau S; Lina B; Fève B; Adnet F; Sabbah M; Rosa-Calatrava M; Maréchal V; Henri J; Slama-Schwok A
Molecules; 2021 Apr; 26(9):. PubMed ID: 33946802
[TBL] [Abstract][Full Text] [Related]
10. Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.
Mirabelli C; Wotring JW; Zhang CJ; McCarty SM; Fursmidt R; Pretto CD; Qiao Y; Zhang Y; Frum T; Kadambi NS; Amin AT; O'Meara TR; Spence JR; Huang J; Alysandratos KD; Kotton DN; Handelman SK; Wobus CE; Weatherwax KJ; Mashour GA; O'Meara MJ; Chinnaiyan AM; Sexton JZ
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34413211
[TBL] [Abstract][Full Text] [Related]
11. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Antiviral Activity of Gemcitabine with 2'-Fluoro-2'-Deoxycytidine and Combination Therapy with Remdesivir against SARS-CoV-2.
Jang Y; Shin JS; Lee MK; Jung E; An T; Kim UI; Kim K; Kim M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557278
[TBL] [Abstract][Full Text] [Related]
13. Quinacrine, an Antimalarial Drug with Strong Activity Inhibiting SARS-CoV-2 Viral Replication In Vitro.
Salas Rojas M; Silva Garcia R; Bini E; Pérez de la Cruz V; León Contreras JC; Hernández Pando R; Bastida Gonzalez F; Davila-Gonzalez E; Orozco Morales M; Gamboa Domínguez A; Sotelo J; Pineda B
Viruses; 2021 Jan; 13(1):. PubMed ID: 33477376
[TBL] [Abstract][Full Text] [Related]
14. AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2
Good SS; Westover J; Jung KH; Zhou XJ; Moussa A; La Colla P; Collu G; Canard B; Sommadossi JP
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33558299
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol and Pterostilbene Inhibit SARS-CoV-2 Replication in Air-Liquid Interface Cultured Human Primary Bronchial Epithelial Cells.
Ter Ellen BM; Dinesh Kumar N; Bouma EM; Troost B; van de Pol DPI; van der Ende-Metselaar HH; Apperloo L; van Gosliga D; van den Berge M; Nawijn MC; van der Voort PHJ; Moser J; Rodenhuis-Zybert IA; Smit JM
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372541
[TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolone Antibiotics Exhibit Low Antiviral Activity against SARS-CoV-2 and MERS-CoV.
Scroggs SLP; Offerdahl DK; Flather DP; Morris CN; Kendall BL; Broeckel RM; Beare PA; Bloom ME
Viruses; 2020 Dec; 13(1):. PubMed ID: 33374514
[TBL] [Abstract][Full Text] [Related]
17. Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle.
Salgado-Benvindo C; Thaler M; Tas A; Ogando NS; Bredenbeek PJ; Ninaber DK; Wang Y; Hiemstra PS; Snijder EJ; van Hemert MJ
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513797
[TBL] [Abstract][Full Text] [Related]
18. Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants.
Nair MS; Huang Y; Fidock DA; Polyak SJ; Wagoner J; Towler MJ; Weathers PJ
J Ethnopharmacol; 2021 Jun; 274():114016. PubMed ID: 33716085
[TBL] [Abstract][Full Text] [Related]
19. Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing.
Glebov OO
FEBS J; 2020 Sep; 287(17):3664-3671. PubMed ID: 32428379
[TBL] [Abstract][Full Text] [Related]
20. Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication.
Pirzada RH; Haseeb M; Batool M; Kim M; Choi S
Cells; 2021 Apr; 10(5):. PubMed ID: 33946869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
